Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|November 1, 2006

Applied Clinical Trials

  • Applied Clinical Trials-11-01-2006
  • Volume 0
  • Issue 0

eShowcase: Clintrace 4.1

Release takes adverse event reporting to a new level, complies with FDA's new rules

Release takes adverse event reporting to a new level, complies with FDA's new rules

Phase Forward Inc.(Waltham, MA) released version 4.1 of its adverse event reporting and regulatory compliance solution software, Clintrace. A result of Clintrace's integration with Cognos Inc.'s ReportNet software, Clintrace now has additional adverse event and operational information reporting capabilities, as well as enhanced data analysis capabilities. Clintrace 4.1 also features compliance with FDA's MedWatch 3500A form, the new online mechanism for mandatory reporting of serious adverse events, potential and actual medical product errors, and product quality problems involving FDA-regulated drugs, devices, biologics, and dietary supplements.

Clintrace 4.1

The integration with Cognos ReportNet, which offers a single authoring environment for creating reports to improve decision making, will let Clintrace users build their own reports without IT involvement. This, the company says, will afford added flexibility and cost- and time-saving opportunities.

Phase Forward Inc., (888) 703-1122, www.phaseforward.com

Articles in this issue

about 20 years ago

Building Your Clinical IT Team

about 20 years ago

Experts Urge Major Overhaul at FDA

about 20 years ago

Recruitment & Consent in India

about 20 years ago

eShowcase: iPlan Flow

about 20 years ago

Meet the EAB: Somesh Nigam

about 20 years ago

Merging eHR & EDC Conference

about 20 years ago

eShowcase: PharmaReady V3.0

Related to this article

© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.